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Background
Duchenne muscular dystrophy (DMD) is the most preva-
lent type of muscular dystrophy and is the result of an X-
linked mutation in the dystrophin gene. The progression
of skeletal muscle damage is rapid in DMD patients and
cardiomyopathy soon follows. We have investigated
whether or not sildenafil citrate, a phosphodiesterase 5
(PDE5) inhibitor, can be used to ameliorate the age-
related cardiac dysfunction in dystrophin-null (mdx)
mice, a mouse model of DMD.
Results
Using echocardiography, we show that chronic sildenafil
treatment prevents several functional deficits in the car-
diac performance of aged mdx mice. Sildenafil treatment
also prevents cardiac fibrosis from developing. Not only
does sildenafil prevent cardiac dysfunction, but it also
reverses established cardiomyopathy when treatment
starts in aged mdx mice. This is the first study to report a
cardioprotective and reversal effect of PDE5 inhibition in
aged mdx mice.
Conclusion
Overall, the data suggest that PDE5 inhibitors could be a
useful treatment for the cardiomyopathy suffered by
DMD patients.
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